Development of a novel ultrashort antimicrobial peptide-levofloxacin conjugate with enhanced synergistic activity against multidrug and levofloxacin-resistant bacterial isolates
Abstract
Background and purpose: Antimicrobial resistance poses a significant global health threat. A previously developed penta-amino acid ultrashort antimicrobial peptide (UP5), with alternating arginine and biphenylalanine units, showed strong antimicrobial activity, particularly in combination with levofloxacin. However, differences in pharmacokinetics between UP5 and levofloxacin may hinder their optimal clinical use. This study aimed to develop a covalent UP5-levofloxacin conjugate that retains the synergistic antimicrobial properties of both UP5 and levofloxacin. Experimental approach: The UP5-levofloxacin conjugate was synthesized and tested for antimicrobial activity against multidrug-resistant gram-positive ( Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis ) and gram-negative bacteria ( Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa ). Hemolytic activity was assessed on human erythrocytes, and selectivity against MDCK cells was determined. Comparative analysis was performed with individual components. Findings/Results: The conjugate exhibited synergistic antimicrobial activity with minimum inhibitory concentration (MIC) values between 2.5 and 20 μM, overcoming levofloxacin resistance. It showed minimal hemolytic activity < 1% and a favorable selectivity index of 4.4-35.2. Cytotoxicity studies indicated selective toxicity towards MDCK cells, with an IC 50 of 88.34 μM, significantly higher than its MIC values. Conclusion and…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.